Terms ending in 2035
Every in-force patent on Biodesix, Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,653,272 | Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment with Immune Response Generating Therapies In force · High confidence | Globeimmune, Inc. | In force | High confidence | |
| US 9,594,085 | Integrated Quantification Method for Protein Measurements in Clinical Proteomics In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 9,477,906 | Classification Generation Method Using Combination of Mini-Classifiers with Regularization and Uses Thereof In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 10,217,620 | Early Detection of Hepatocellular Carcinoma in High Risk Populations Using Maldi-Tof Mass Spectrometry In force · High confidence | The Board of Regents of the University of Texas System | In force | High confidence | |
| US 9,563,744 | Method of predicting development and severity of graft-versus-host disease In force · High confidence | Biodesix Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Biodesix, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.